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Although the molecular mechanisms underlying psychiatric illnesses such as depression, bipolar disorder and schizophrenia remain
incompletely understood, there is increasing clinical, pharmacologic, and genetic evidence that G protein-coupled receptors (GPCRs) play critical
roles in these disorders and their treatments. This perspectives paper reviews and synthesizes the available data. Dysfunction of multiple
neurotransmitter and neuropeptide GPCRs in frontal cortex and limbic-related regions, such as the hippocampus, hypothalamus and brainstem,
likely underlies the complex clinical picture that includes cognitive, perceptual, affective and motoric symptoms. The future development of novel
agents targeting GPCR signaling cascades remains an exciting prospect for patients refractory to existing therapeutics.
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Although major psychiatric diseases such as mood disorders
and schizophrenia are among the most common and destructive
of all human illnesses, the molecular and cellular mechanisms
underlying their complex pathophysiology remain to be fully
elucidated. Attempts to comprehend the biochemical under-
pinnings of major psychiatric disorders began in earnest as
clinically effective mood-altering drugs began to appear in the
late 1950s and early 1960s. Studies were, by and large, designed
to detect relative excess or deficiency of individual neuro-
transmitters associated with pathological states; not surpris-
ingly, progress in unraveling the neurobiology of these complex
disorders was slow using such strategies in isolation. Psychiatry,
like much of the rest of medicine, has entered a new and
exciting age demarcated by current rapid advances and the
future promises of genetics, molecular and cellular biology, and
improving imaging technologies. Recent years have witnessed a
more wide-ranging understanding of the neural circuits and the
various mechanisms of synaptic transmission, a further
elucidation of the molecular mechanisms of receptor and
postreceptor signaling, a finer understanding of the process by
which genes code for specific functional proteins, and the
identification of causative genes in many neurological disorders
that in toto reduce the complexity in gene to behavior pathways
[1]. In other areas of medicine, the recent molecular medicine
revolution has already had an immediate impact; unfortunately,
clinical translation of these findings to psychiatric disorders hasnot been as rapid. In addition to the sheer complexity of the
CNS, unraveling the etiology/pathophysiology of complex
psychiatric disorders is hampered by numerous additional
obstacles, including lack of a defined pathology, no direct tissue
accessibility, and the daunting fact that the complexity of
behavior is not simply the sum of its parts [1]. Nevertheless,
major advances in our understanding of the role of G protein-
coupled receptors (GPCRs) in the pathophysiology and
treatment of major psychiatric disorders have indeed been
made. In this perspectives article, we review and synthesize the
available data, and discuss their implications for the strategic
development of improved therapeutics. Due to space considera-
tions, we have narrowed the scope of this review to the major
psychiatric disorders, and the major families of GPCRs
implicated, and have cited reviews in place of primary papers
as often as possible.
2. Clinical overview
It is beyond the scope of this article to discuss the role of
GPCRs in all psychiatric disorders; here we limit ourselves to a
discussion the most severe disorders—schizophrenia and mood
disorders. Since the readership of the journal may be less
familiar with the clinical facets of these disorders, we first
provide a brief clinical overview, prior to embarking on a
discussion of GPCRs.
Mood disorders, such as major depression (MD) and bipolar
disorder (BPD, previously referred to as manic–depressive
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illnesses. The Global Burden of Disease Study has identified
major mood disorders among the leading causes of disability
worldwide [2], and the World Health Organization estimates
that mental illness accounts for 40% of disability funding in the
U.S. [3].
2.1. Mood disorders
MD has a lifetime incidence of about 15% [4], and affects
twice as many women as men. There is a significant genetic
component to the disorder; studies report an approximately
three-fold increased risk of MD in first-degree relatives of
probands with the disorder compared to the general population
[4,5]. The course of MD is characterized by episodes of
depressed mood, suicidal ideation, anhedonia, impaired sleep,
changes in psychomotor activity, and impaired memory and
concentration. Suicide is the cause of death in up to 15% of
individuals with this disorder [6]. There are several classes of
antidepressant medications used to treat MD, including tricyclic
antidepressants, selective serotonin reuptake inhibitors (SSRIs),
and others that affect reuptake of monoamines such as
norepinephrine, dopamine and serotonin.
BPD has an approximate lifetime incidence of 1% [8] and is
characterized by two seemingly opposite mood states: mania
and depression. It is equally prevalent in men and women [6].
The manic stages of BPD are characterized by a hyperaroused
state (either euphoric or dysphoric), increases in motor activity,
racing thoughts, impaired judgment, and an apparent decreased
need for sleep [6,8]. The depressive phases of the illness present
with similar symptomatology as those seen in MD. As with
MD, suicide is the cause of death in up to 15% of individuals
with BPD [6]. BPD is typically treated with the class of
medications known as mood stabilizers (reviewed in [8]).
Although other types of medications, including atypical
antipsychotics, are also used to treat BPD, most studies have
focused on mood stabilizers such as lithium, valproic acid and
carbamazepine as the standard of treatment for this disorder.
2.2. Schizophrenia
Schizophrenia has a lifetime prevalence of approximately
1% [3] and affects men and women equally. Family prevalence,
twin, and adoption studies have all demonstrated that there is a
genetic component to this disorder; individuals with a first
degree relative with schizophrenia are ten times more likely to
be affected than an individual in the general population.
Schizophrenia is a psychotic disorder characterized by delu-
sions, hallucinations and/or thought disorganization (“positive
symptoms”) and flattened affect, poverty of thought and/or
avolition (“negative symptoms”). The cognitive impairments in
schizophrenia (sometimes quite profound) are increasingly
being recognized as playing a major role in the long-term
disability observed in this devastating illness. Not surprisingly,
much of the new medication strategies have focused on
improving the cognitive deficits (vide infra). The suicide rate
among schizophrenic individuals is twice that of the generalpopulation [3]. Like mood disorders, schizophrenia is asso-
ciated with a significant increase in medical comorbidities [3], a
difficulty compounded by the increasingly recognized fact that
newer antipsychotic medications can cause medical complica-
tions such as obesity and diabetes. The economic cost of
managing a patient with schizophrenia is estimated to be six
times that of a patient with a myocardial infarction [3].
Schizophrenia is generally treated with antipsychotic medica-
tions. The use of first generation, or typical, antipsychotics, has
largely given way to the use of newer, second generation, or
atypical, antipsychotics which have equivalent efficacy, but
different and arguably more favorable side effect profiles.
3. GPCRs and mood disorders
Although most families of medications currently used to treat
affective illnesses have been in use since the 1950s, our
understanding of their mechanisms, and the etiology of the
underlying diseases, is still incomplete. The “pharmacological
bridge” approach to biomedical research refers to the develop-
ment of etiologic theories of disease based on the known
mechanism of effective pharmacologic treatments. In mood
disorders, this approach first led to the monoamine theory. As
discussed below, monoamines are still considered to be among
the most important neurotransmitters in the pathophysiology of
mood disorders. However, other neurotransmitter systems, most
notably the glutamatergic, cholinergic and GABAergic systems,
have also been implicated.
3.1. G protein-coupled noradrenergic receptors and mood
disorders
The noradrenergic system was one of the first neurotrans-
mitter systems to be suspected to play a role in affective
disorders. Many initial studies indirectly addressed the question
of noradrenergic receptor abnormalities in these disorders by
investigating expression in peripheral cells. Further evidence
has come from postmortem studies, pharmacologic challenge
experiments, studies to elucidate the mechanism of action of
effective medications, and genetic studies.
3.1.1. Peripheral blood cell studies
Due to the accessibility of platelets and lymphocytes, alpha2
and beta2 adrenergic receptor expression in peripheral cells has
been extensively studied in mood disorders. It must be
acknowledged at the outset that there may be several problems
with the assumption that changes in adrenergic receptors on
peripheral cells reflect similar alterations in the CNS. To begin
with, receptors on blood cells are, by definition, noninnervated,
exist in a markedly different environment, and may therefore
poorly reflect central, innervated, adrenergic receptors. Another
major problem when interpreting studies of dynamic receptor
regulation in blood cells is that white blood cell counts and the
relative proportions of subsets of lymphocytes may vary.
Recruitment of cells with different characteristics into the
circulation may frequently explain altered receptor function.
Nevertheless, in some cases, similar findings have been found
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studies as have been observed in peripheral cell studies.
3.1.1.1. Alpha2-adrenergic receptors. Studies of alpha2-
adrenergic receptor (alpha2-AR) levels in platelets of de-
pressed patients have yielded mixed results. A series of studies
using yohimbine-alkaloid radioligands showed no differences
in receptor numbers, while other studies using partial or full
agonists have reported an increased maximal binding capacity
in depressed patients relative to controls (reviewed in [7]). The
findings of these latter studies have been called into question,
however, because the ligands have been discovered to bind to
nonadrenergic imidazoline sites [9–11], which are present on
platelets [12]. Thus the alpha2 receptor hypersensitivity
theory of depression, based on these initial findings, remains
in question.
Few studies have addressed this question in bipolar disorder.
One such study found a trend toward increased density of
alpha2-ARs on platelets of patients with bipolar disorder [13].
3.1.1.2. Beta2-adrenergic receptors. Although studies inves-
tigating the levels of beta2-adrenergic receptors (beta2-ARs) in
peripheral cells have yielded inconsistent results (reviewed in
[7]), multiple studies have reported decreased beta-AR-
stimulated adenylate cyclase (AC) activity in leukocytes of
depressed patients [14–19]. This is hypothesized to be due to a
disruption of the receptor/Gs/AC complex [20]. For both the
alpha2 and beta2 findings in peripheral cells, it remains to be
determined which abnormalities relate specifically to the
pathogenesis of mood disorders, and which are related to
nonspecific effects of stress, or homeostatic mechanisms [21].
3.1.2. Postmortem studies
3.1.2.1. Alpha-adrenergic receptors. Limited data suggests
alpha2-AR levels are altered in the postmortem brains of
depressed suicide victims (reviewed in [22]). These preliminary
findings are limited by methodological considerations regarding
the use of postmortem brains (e.g., postmortem delay, cause of
death, drug history) and by the fact that some of the ligands used
also bind imidazoline sites, as discussed above.
3.1.2.2. Beta-adrenergic receptors. Several studies have
reported an increase in beta-AR density in the brains of suicide
victims [23], including specifically in cortex [24], while at least
one other study found no difference in cortex [25].
3.1.3. Pharmacologic challenge experiments
3.1.3.1. Alpha2-adrenergic receptors. Numerous studies have
investigated the role of alpha2-ARs in mood disorders using
pharmacologic challenge strategies. Multiple studies have
compared the downstream effects of alpha2-AR agonists
(such as clonidine) or antagonists (such as yohimbine) on
plasma MHPG, blood pressure, sedation and cortisol in
depressed patients compared to normal controls. While the
findings have not been entirely consistent, most do not showsignificant differences (reviewed in [21]). However, multiple
studies have consistently demonstrated a significant decrease in
growth hormone (GH) response to the alpha2-AR agonist
clonidine [26–32], supporting the hypothesis of postsynaptic
alpha2-AR subsensitivity in depressed patients.
Far fewer studies have addressed the question of alpha2-AR
sensitivity in bipolar disorder. Several such studies have
demonstrated a blunted GH response in manic and/or bipolar
depressed states (reviewed in [21]). Similar findings have been
reported in panic disorder, general anxiety, and obsessive–
compulsive disorder, suggesting that it may be a nonspecific
response to stress and/or elevated norepinephrine [33–36].
3.1.4. Effects of antidepressants and mood stabilizers
3.1.4.1. Alpha-adrenergic receptors. Antidepressants have
been shown to decrease alpha2-ARs and increase alpha1-ARs
in animal studies (reviewed in [22]). Long-term lithium
administration has been shown to attenuate alpha2-AR-
mediated behavioral effects [37].
3.1.4.2. Beta-adrenergic receptors. Most studies have shown
a consistent pattern of beta-AR downregulation in response to
long-term treatment with antidepressants of all classes or
electroconvulsive therapy (ECT) [22,38–42]. Long-term
administration of desipramine, an antidepressant, results in
uncoupling of beta-AR and Gs in cortex [43,44]. Both receptor
downregulation and receptor-G protein uncoupling result in
decreasing downstream cAMP signaling [43–45]. Desipramine
also inhibits the breakdown of the beta-AR high affinity
complex [46], which interferes with the downstream activation
of adenylate cyclase [47].
Most studies addressing the effects of mood stabilizers have
focused on lithium. Studies investigating the effects of lithium
on adrenergic receptor binding in rat brain have been
inconclusive (reviewed in [21]), but have consistently shown
an inhibition in beta-AR-stimulated cAMP [48]. Lithium does
not block antidepressant-induced beta-AR downregulation [49].
Fewer studies have investigated the effect of other mood
stabilizers in this system. One in vitro study found that valproic
acid caused decreased beta-AR density, as well as cAMP
production and G-alpha-s levels [50], while other studies
investigating beta-AR density in response to valproic acid have
produced mixed findings. Carbamazepine has been shown to
induce upregulation of beta-ARs, and, consistent with other
mood stabilizers, carbamazepine decreases beta-AR-induced
AC activity (reviewed in [21]).
3.1.5. Receptor polymorphisms
Studies examining alpha2-AR polymorphisms have not
found an association with suicide or depression [51,52]. One
study examining a beta1-AR polymorphism, G1165C, found a
nonsignificant trend toward an association with an improved
response to antidepressant treatment in depressed patients [53].
Most recently, a study investigated the effects of iv infusion of
yohimbine on subjects carrying an-frame deletion of the
alpha2C-adrenoreceptor subtype (alpha2CDel322–325) [54].
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ism had higher total body noradrenaline spillover than did
heterozygotes; moreover, yohimbine produced larger, more
sustained increments in noradrenaline spillover, heart rate, and
anxiety in homozygotes than in the other groups. Since the
pattern of catecholaminergic responses is similar to what has
been observed in mood disorders [7], the role of this receptor
polymorphism in these disorders is under investigation.
3.2. G protein-coupled serotonergic receptors and mood
disorders
The efficacy of medications with serotonergic effects in the
treatment of depression has been the primary impetus for
proposing a role for serotonin in mood disorders. In addition to
pharmacologic data, there is considerable evidence for
serotonergic abnormalities in patients with depression, although
the data for bipolar disorder is less clear. Some of the most
compelling recent data that support a role for serotonin in mood
disorders comes from the identification of receptor polymorph-
isms associated with disease susceptibility and/or treatment
response.
3.2.1. Pharmacologic challenge, postmortem and imaging
studies
Depressed patients have been shown to exhibit a blunted
response of the serotonin system, as measured by fenfluramine-
induced prolactin release [55], although other studies have not
replicated this finding. This blunting was more pronounced in
the subset of patients who made high lethality suicide attempts
[56] and those with anger attacks [57].
3.2.1.1. 5HT1A receptors. Several studies have shown blunted
responses to 5HT1A receptor agonists and decreased 5HT1A
receptor binding postmortem in depressed patients [58,59],
although some studies have found an increase in the number of
5HT1 receptors in prefrontal cortex of suicide victims [60], or
increased 5HT1A binding in depressed patients [61]. PET studies
have demonstrated region-specific changes in 5HT1A receptor
binding in depressed subjects compared to healthy controls
[62,63]. It is speculated that the mechanism of decreased 5HT1A
receptor binding is via increased cortisol secretion, which inhibits
5HT1A mRNA expression (reviewed in [21]).
3.2.1.2. 5HT1B receptors. In a recent report, Svenningsson
and colleagues [64] demonstrate that 5HT1B receptors are
modulated by p11, which is decreased in an animal model of
depression and in brain tissue from depressed patients, and is
increased in rodent brains by antidepressants or ECT. The
authors show that overexpression of p11 in mice increases
5HT1B receptor function and mimics certain behaviors seen in
response to antidepressant treatment, while p11 knockout mice
demonstrate a depression-like phenotype and have reduced
responsiveness to 5HT1B receptor agonists. The intriguing
findings from this study suggest a dynamic relationship
between 5HT1B receptors and p11 that may be involved in
the pathophysiology of depression.3.2.1.3. 5HT2 receptors. Postmortem studies have found an
increase in the number of 5HT2A and 5HT2C receptors in the
brains of patients with depression and in suicide victims (for
example, see [65,66]), although other studies have found
contradictory results (reviewed in [67,68]). Imaging studies
[68,69], and studies investigating 5HT2A receptors on platelets
[21] have similarly yielded mixed results.
3.2.2. Effects of antidepressants and mood stabilizers
3.2.2.1. 5HT1A receptors. The postulated role of 5HT1A
receptors in mood disorders is supported by evidence that
chronic antidepressant treatment results in desensitization of
somatodendritic 5HT1A autoreceptors in the dorsal raphe and
subsequent enhancement of serotonergic transmission in
hippocampus [70,71]. Abnormalities in 5HT1A receptor
binding in bipolar patients are normalized by chronic lithium
administration [21]. Chronic antidepressant treatment has also
been shown to increase 5HT1A receptor-G protein uncoupling
[72].
3.2.2.2. 5HT2 receptors. Antidepressants have been shown to
downregulate 5HT2A receptor binding in cortex [73]. The
evidence for the role of 5HT2A receptors in the mechanism of
action of mood stabilizers is much less clear. Studies
investigating 5HT2A receptor binding following chronic
lithium administration have produced mixed results. Most
suggest that lithium induces a decrease in 5HT2 receptor
binding, with the strongest evidence in the hippocampus
(reviewed in [21]), although studies in platelets have demon-
strated a lithium-induced increase in 5HT2A receptor binding
capacity in bipolar patients [74].
3.2.3. Receptor polymorphisms
3.2.3.1. 5HT1A and 5HT1B receptors. Data from several
studies support a role for the 5HT1A receptor in depression and
treatment outcome. Lemonde and colleagues [75,76] report an
association of the C-1019G 5HT1A promoter polymorphism
with major depression and suicide, and with response to
flibanserin, a 5HT1A agonist antidepressant. Other studies have
similarly reported an association between antidepressant
response and both this polymorphism [61,77] and Gly272Asp
[78]. Arias and colleagues [79] found that a combined genetic
effect of the HTR1A gene, which encodes the 5HT1A receptor,
and the SLC6A4 gene, which encodes the serotonin transporter,
influenced clinical outcome of depressed patients treated with
the antidepressant citalopram. The G861C locus of the 5HTR1B
gene has been shown to be associated major depression, but not
bipolar disorder [80], although another study did not find such
an association [81].
3.2.3.2. 5HT2A receptors. A promoter polymorphism in the
5HTR2A gene, A-1438G, has been shown to be associated with
major depression [82]. Many studies have attempted to identify
an association between 5HT2A receptor polymorphisms and
bipolar disorder, but these studies have yielded few demonstrated
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has repeatedly not been found to have an association with bipolar
disorder [83–85]. However, several studies have shown positive
associations between other 5HT2A receptor polymorphisms
(C516T, C1354T and A-1438G) and bipolar disorder [86–88].
Choi and colleagues [89] found an association between the A-
1438G polymorphism of the 5HT2A receptor and treatment
response to the antidepressant citalopram, although another
group reported finding no such association using the antide-
pressant fluvoxamine [90]. Some of the most compelling
evidence for a role for the 5HT2A receptor in the treatment of
mood disorders comes from the Sequenced Treatment Alter-
natives for Depression (STAR*D) study. A significant associa-
tion was found between treatment outcome and a marker in
HTR2A, which encodes the 5HT2A receptor [91]. This study
searched for genetic predictors of treatment outcome in 1953
patients with major depression, and detected a significant and
reproducible association between treatment outcome and an
intronic marker in the 5HT2A receptor gene. Moreover, the A
allele (which was associated with a higher rate of response) was
over six times more frequent in white than in black participants,
and treatment was less effective among black participants [91].
Taken together with prior neurobiological findings, these new
genetic data make a compelling case for a key role of HTR2A in
the mechanism of antidepressant action; furthermore, the
polymorphisms in this receptor may also contribute to racial
differences in outcomes of antidepressant treatment.
3.2.3.3. 5HT2C receptors. Lerer and colleagues [92] demon-
strated an association between a 5HT2C receptor polymorphism
and both major depression and bipolar disorder in a population
derived from nine different European countries. Gutierrez and
colleagues have investigated this same 5HT2C receptor
polymorphism in bipolar disorder and have demonstrated a
weak association in female bipolar patients that was not seen in
a mixed gender sample [93,94]. Another group similarly found
a trend toward an association between a 5HT2C polymorphism
and female, but not mixed gender, bipolar patients [95].
3.3. G protein-coupled dopaminergic receptors and mood
disorders
Although dopamine has been at the center of schizophrenia
research for decades, it has been relatively under-examined with
respect to its role in mood disorders. Nevertheless, there are
several lines of evidence pointing to dopamine's role in these
illnesses. The midbrain dopamine system regulates motor
activity, motivation and reward pathways, and the mesolimbic
dopamine system plays a critical role in goal-directed behavior.
All of these functions are significantly disrupted in depression
and mania. Multiple pharmacologic agents that act on dopamine
receptors have effects onmood symptoms, further supporting the
role of G protein-coupled dopamine receptors in mood disorders.
3.3.1. Imaging and pharmacologic studies
SPECT studies have demonstrated increased D2/D3 receptor
availability in the striata of depressed patients with bipolardisorder (reviewed in [21]). Two such studies correlated
increased receptor binding with psychomotor retardation
[96,97].
Antipsychotics that block dopamine receptors are effective
against acute mania. Multiple dopamine receptor agonists,
including bromocriptine and pramipexole, have significant
antidepressant properties, both in bipolar and unipolar depressed
states [98]. Pramipexole has been found to be effective alone
[99] and as an adjunct to selective serotonin reuptake inhibitor
(SSRI) antidepressants [100] or mood stabilizers [101].
Dopamine receptor binding studies comparing lithium to
placebo have been inconclusive. However, lithium has been
shown to inhibit haloperidol-stimulated dopamine receptor
upregulation and agonist-induced supersensitivity [21].
3.3.2. Receptor polymorphisms
3.3.2.1. D1 receptor. Although several studies have failed to
find mutations in the D1 receptor gene in bipolar disorder
[102,103], the results of two studies suggest an association
between the D1 receptor A48G polymorphism and bipolar
disorder [104,105].
3.3.2.2. D2 receptor. Numerous studies have attempted to
identify an association between D2 receptor polymorphisms
and bipolar disorder and have failed to find such an association.
Two studies, however, have reported positive findings. In a
large European multicenter study, Massat and colleagues [106]
found a significant association between the D2 receptor and
bipolar disorder. In a smaller study of Han Chinese patients with
bipolar disorder, Li and colleagues [107] found an association
with a D2 receptor polymorphism which was not replicated
when studied in a Caucasian population, suggesting a possible
race-specific risk factor.
3.3.2.3. D3 receptor. One small study has found an associa-
tion between a D3 receptor polymorphism and unipolar
depression [108]. Multiple studies have failed to show clear
evidence for the involvement of the D3 receptor locus in bipolar
disorder.
3.3.2.4. D4 receptor. Several studies have investigated a
possible role for the D4 receptor in depression. Lopez Leon and
colleagues [109] performed a meta-analysis of these studies and
found a significant association between the D4 receptor gene 48
base pair repeat polymorphism and unipolar depression but not
bipolar disorder.
3.4. G protein-coupled cholinergic receptors and mood
disorders
There has been a long-standing interest in the potential
involvement of the cholinergic system in bipolar disorder, based
primarily on studies indicating the prominent mood and
behavioral effects of cholinergic agonists and antagonists.
(reviewed in [21]). Most studies documenting cholinergic
receptor sensitivity in mood disorders have been quite indirect.
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its onset can be induced earlier in normal volunteers by
cholinergic agents. Several research groups have reported a
faster induction of REM sleep with arecoline (a cholinergic
agonist) in medication-free mood disorder patients (primarily
bipolar disorder) (reviewed in [21]).
Recently, Cannon and associates [110] used positron
emission tomography and [18F]FP-TZTP (fluorodopa F 18
[3-(3-[3-fluoroproply]thio)-1,2,5-thiadiazol-4-yl]-1,2,5,6-tetra-
hydro-1-methylpyridine), a selective muscarinic2 (M2) receptor
radioligand, to assess the binding potential of M2 receptors in
vivo. They found significantly lower M2 binding in anterior
cingulate in BPD compared with both MD and control groups.
Many antidepressants, including tricyclics and serotonin
reuptake inhibitors, have anticholinergic properties, although
the relevance to their antidepressant action is not clear. Studies
have produced conflicting reports regarding the effect of lithium
on muscarinic receptor binding. Lithium has been shown to
block muscarinic receptor supersensitivity without affecting the
number of receptor binding sites, suggesting it acts at a post-
receptor site [111].
One study has shown an increased frequency of homo-
zygosity at the A1890T polymorphism in the cholinergic
muscarinic receptor 2 (CHRM2) gene among women, but not
men, with major depression [112].
3.5. G protein-coupled GABAergic receptors and mood
disorders
There is some evidence that G protein-coupled GABA-B
receptors play a role in mood disorders. Baclofen, a GABA-B
receptor agonist, has been shown in a small number of patients
to induce a reversible depression that remits following
discontinuation of the agent [113]. Chronic administration of
mood stabilizers such as lithium, valproic acid and carbama-
zepine increases GABA-B receptors in hippocampus [114,115],
although the relevance of this finding to their pharmacologic
effect is not known.
3.6. G protein-coupled glutamatergic receptors and mood
disorders
It is surprising that the glutamatergic system has only
recently undergone extensive investigation with regard to its
possible involvement in the pathophysiology of mood
disorders, since it is the major excitatory neurotransmitter in
the CNS, known to play a role in regulating the threshold for
excitation of most other neurotransmitter systems. There is
now mounting evidence for a role of the glutamatergic system
in the pathophysiology and treatment of mood disorders [116–
118]. To date, most of the available evidence implicates
ionotropic receptors – both NMDA [118] and AMPA [119] –
in the treatment of mood disorders. In view of our focus on
GPCRs, these will not be discussed here; interested readers are
referred to recent reviews dealing with a broader discussion of
the role of the glutamatergic system in mood disorders [116–
118].3.7. G protein-coupled neuropeptide receptors and mood
disorders
Neuropeptides are short-chain amino acids that act as
neurotransmitters in numerous brain circuits; indeed, the
contribution of altered endocrine function to pathological
mood states was among the earliest themes in biological
psychiatry. The actions of a single neurohormone peptide on a
wide range of brain receptors characteristically span a much
longer time period than the actions of monoamines. The
influence of neurohormones on neurons may have been
elaborated for teleological reasons. The possibility that one
substance effectively commands and organizes multiple
coordinated physiological and behavioral responses is consis-
tent with the importance of certain peptides in the long-term
phasic changes typical of mood disorders [21]. The voluminous
data implicating abnormalities of various neurohormones and
neuropeptides are reviewed extensively elsewhere ([21] and
other textbooks); here, we limit ourselves to those neuropeptide
GPCRs that are being extensively investigated in the treatment
of mood disorders.
3.7.1. Corticotropin-releasing factor (CRF) receptors
CRF has become one of the most extensively studied of all
the neuropeptides in relation to its potential role in mood
disorders, due to demonstrations of abnormalities in patients
and in animal models (reviewed in [21,120,121]). Preclinical
studies using animal behavior models have indicated that CRF
receptor antagonists, specifically of the CRF receptor-1
subtype, have anxiolytic and antidepressant activity [122].
These results led to the testing of a CRF receptor-1 antagonist,
R121919, in an open trial in 24 patients with depression [123].
Initial results were encouraging, and further clinical studies are
anticipated. However, at least two genetic linkage and
association studies have failed to support the linkage of CRF
polymorphisms to bipolar illness [124,125].
3.7.2. Neurokinin1 (NK1) receptors
Preclinical behavioral studies involving pharmacological or
genetic inactivation of the neurokinin1 receptor [126] sug-
gested a promising target for antidepressant and/or anxiolytic
drug discovery. Importantly, genetic or pharmacologic block-
ade of NK1 receptors was observed to induce some of the
same long-term neural effects as standard antidepressants on
cell signaling molecules such as BDNF and hippocampal
neurogenesis [127]. However, despite the promising preclinical
data, a recent pooled analysis of five 8-week randomized,
double-blind placebo-controlled multicenter studies of the
substance P antagonist aprepitant in major depression found
lack of efficacy [128].
3.7.3. Neuropeptide Y (NPY) receptors
NPY, the most abundant peptide in mammalian brain, is a 36-
amino acid polypeptide, rich in tyrosine residues, with a
molecular weight of 4272 Daltons. There are 6 recognized NPY
receptor subtypes (Y1–Y5) present in the brain and other
tissues. In the brain, major sites of NPY production are the
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hypothalamus, where the highest concentrations are present. In
fact, NPY is the most potent physiological stimulant of feeding
behavior yet described [129]. A recent report found decreased
CSF concentrations of NPY in patients with treatment-resistant
unipolar major depression [130]. The upregulation of amygdala
NPY mRNA levels after chronic stress suggests potential
involvement in the adaptive responses to stress exposure [131].
4. GPCRs and schizophrenia
4.1. G protein-coupled dopaminergic receptors and
schizophrenia
The dopamine hypothesis of schizophrenia remains the
primary explanatory hypothesis for the florid psychotic
symptoms of the disease (notably hallucinations and delusions),
although it is clear that the true pathophysiology is much more
complex. The hypothesis that schizophrenia is caused by
hyperactivity of limbic dopaminergic transmission arose from
the fact that all effective antipsychotic agents block dopamine
D2 receptors, and amphetamine, which facilitates dopamine
release, induces schizophrenia-like psychotic symptoms. The
majority of data supporting the dopamine theory continues to
come from studies of antipsychotic medications (see below).
4.1.1. Postmortem and imaging studies
Many studies have looked for evidence of dopamine receptor
dysregulation in schizophrenic patients, with mixed results. In
contrast with some early findings, recent studies have generally
been consistent in showing no abnormalities in D2 receptor
density in schizophrenia (reviewed in [132,133]). With regard
to other dopamine receptor subtypes, one intriguing study
demonstrated decreased D1 receptor density in prefrontal cortex
by PET and correlated this finding with the severity of negative
symptoms and impairment in prefrontal cognitive performance
[134]. One report demonstrated an increase in D3 receptor in the
nucleus accumbens [135], while another showed decreased D3
receptor levels in parietal and motor cortex [136]. Studies have
shown decreased D3 and D4 mRNA in orbitofrontal cortex
[137] and increased D4 receptor levels in putamen in
schizophrenia [138].
4.1.2. Effects of antipsychotic medications
The hyperactive dopamine theory was initially developed in
light of the high D2 affinity of typical antipsychotics and the
tight correlation between receptor affinity and clinical response
[139]. PETand SPECT studies confirm the relationship between
D2 receptor occupancy and therapeutic effect: typical anti-
psychotic efficacy appears to be optimized at 65–70% D2
receptor occupancy, and greater than 80% occupancy signifi-
cantly increases the risk of extrapyramidal symptoms (EPS), a
known side effect [140].
Several lines of evidence suggest that D2 receptor binding is
insufficient to fully account for the pathophysiology of
schizophrenia. First, not all patients with schizophrenia improve
on typical antipsychotics, despite 70% or greater receptoroccupancy [140]. Second, typical antipsychotics effectively
treat only about 70% of positive symptoms [133] and are
relatively ineffective with respect to negative and cognitive
symptoms. Third, the timecourse of receptor blockade, which
occurs in a matter of hours, does not correlate with the
timecourse of clinical effect, which occurs over days or weeks
[133,140]. It is hypothesized that downstream or longer-term
changes mediate the clinical effect; for example, long-term
administration of typical antipsychotics has been shown to
upregulate D2 receptors [140]. Finally, atypical antipsychotics
have overall lower D2 receptor binding affinity than typical
antipsychotics but are not less effective. The atypical anti-
psychotics clozapine and quetiapine, for example, exert
therapeutic effects at less than 70% occupancy [140].
Together these data suggest that although some level of D2
blockade is necessary for antipsychotic effects, it is not
sufficient. Atypical antipsychotics act on other dopaminergic
receptors subtypes as well as non-dopaminergic receptors.
Compared to typical antipsychotics, atypicals have a much
stronger binding affinity for D4 receptors as well as multiple
other GPCRs, including D1, D3, 5HT1A, 5HT2A, 5HT2C, and
muscarinic receptors. Typical antipsychotics have been shown
to induce increased expression of D1 receptors [141].
Clinically, typical antipsychotics are effective only against
positive symptoms, presumably via D2 receptor antagonism,
while atypical antipsychotics are additionally effective with
regard to negative and cognitive symptoms. D2 antagonists can
block stimulant-induced psychosis in healthy individuals [142].
Dopamine agonists have been shown to improve negative
symptoms and prefrontal cognitive performance [143], and
these symptoms, when induced by amphetamine treatment, are
not blocked by D2 antagonists [144]. Taken together these data
lend support to a newer and more complex hypothesis of
schizophrenia in which hypoactive D1 receptors in the
mesocortical pathway correlate with negative symptoms and
hyperactive D2 receptors are associated with positive symptoms
[145].
4.1.3. Receptor polymorphisms
4.1.3.1. D2 receptors. Given the above findings, numerous
researchers have investigated the role of D2 receptor polymorph-
isms in schizophrenia. Although controversial, multiple reports,
both primary studies and meta-analyses, have demonstrated a
positive association between the D2 receptor Ser311Cys
polymorphism and schizophrenia [146–149]. Other studies,
however, have found no association [150,151]. One study did
find an association between Ser311Cys and symptom severity,
although not diagnosis [152]. A second polymorphism from the
D2 receptor promoter region, −141C Ins/Del, has also been
shown by several groups to be associated with schizophrenia
[153–156]. Other reports have implicated other D2 receptor
polymorphisms such as C957T [157], His313 [158], and the
Taq1A locus [159]. Several studies have shown an association of
−141C Ins/Del with timing or degree of response to antipsychotic
medications, with a more favorable response associated with the
−141C Ins allele [160–162], although other studies have not
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similarly shown an association between treatment response and
the Taq1A locus [162,163,165,166], the Ser311Cys polymorph-
ism [167] and the His452Tyr polymorphism [168].
4.1.3.2. Other dopamine receptor subtypes. The D3 receptor
polymorphism Ser9Gly is the most widely studied for the D3
receptor, but results correlating it with susceptibility to
schizophrenia have been inconclusive [169–173]. Multiple
studies have demonstrated an association between this poly-
morphism and response to antipsychotics [174–177]. There is
some discrepancy among these studies regarding which subset
of symptoms primarily correlates with this polymorphism, and
one published study failed to find any correlation [173]. A
pattern of association is seen between the Ser9 allele and
response to typical antipsychotics, and between the Gly9 allele
and response to atypical antipsychotics (reviewed in [162]).
Other D3 receptor variants that have shown association with
schizophrenia include G-205A [169,171], G-7685C [169], and
G-712C [171]. Mixed results have been reported regarding the
BalI [178–184] and MscI [185,186] restriction sites in exon 1.
In the D4 receptor, a 48 base pair repeat in exon 3 has been
the subject of much research; however studies have failed to
show a significant association with schizophrenia [187–190].
Although one study reports an association between this
polymorphism and response to the atypical antipsychotic
clozapine [191], two other studies showed no such correlation
[192,193].
4.2. G protein-coupled serotonergic receptors and
schizophrenia
Although evidence for changes in serotonin receptors in
schizophrenia has been controversial, pharmacologic data, such
as the serotonergic effects of pro-psychotic drugs of abuse and
of atypical antipsychotic medications, suggest a role for
serotonin in this disease.
4.2.1. Postmortem and imaging studies
Some postmortem studies show a decrease in 5HT2A
receptors in schizophrenia, although others do not (reviewed
in [194]). One PET study showed no difference between
untreated schizophrenic patients and controls with respect to
5HT2A receptor expression in cortex [194], while another
demonstrated an increase in both 5HT1 and 5HT2A receptors
[195].
4.2.2. Pharmacologic studies
The strongest evidence for a role for serotonin in schizo-
phrenia comes from pharmacologic studies. D-lysergic acid
diethylamide (LSD) can cause psychotic symptoms in healthy
individuals, and its structural similarity to serotonin prompted
further investigation of this neurotransmitter system in
psychosis [196]. It is now known that LSD exhibits effects on
the serotonin system in the raphe nucleus via 5HT1A receptors,
and most likely induces hallucinations via agonist action at the
5HT2A receptor (reviewed in [196,197]).The discovery of atypical antipsychotics, which block the
5HT2A receptor in addition to dopamine receptors and others,
prompted the development of the serotonin–dopamine antag-
onism theory. This theory states that the higher the ratio of
5HT2A receptor affinity to D2 receptor affinity, the more
“atypical” the antipsychotic, i.e., the more effective and the less
likely to produce EPS (reviewed in [140]). The atypicals
clozapine, risperidone, olanzapine and ziprasidone demonstrate
greater than 80% occupancy of cortical 5HT2A receptors at
therapeutic doses [140]. It is hypothesized that 5HT2A receptor
antagonism partially reverses D2 receptor blockade, resulting in
less EPS [140,198]. The 5HT2A effects of these medications are
not sufficient to mediate their antipsychotics effects, however,
as 5HT2A receptor antagonist monotherapy with M-100907 is
ineffective [199].
In addition to receptor blockade, atypical antipsychotics
have also been found to induce subcellular redistribution of the
5HT2A receptor. Willins and colleagues [200] demonstrated
that atypical antipsychotics with high affinity for the 5HT2A
receptor (clozapine, olanzapine and risperidone) induce inter-
nalization of the 5HT2A receptor in fibroblasts in vitro.
Consistent with this finding, they also report loss of 5HT2A
receptor immunoreactivity on pyramidal neurons in response to
clozapine and olanzapine [200].
Action at the 5HT1A receptor is thought to synergize with
actions at the dopamine receptor and 5HT2A receptor in the
treatment of schizophrenia. Some studies have demonstrated
that 5HT1A agonists augment the effect of dopamine anta-
gonists [201], and it is hypothesized that the partial 5HT1A
agonism of clozapine [202] and aripiprazole [203] contri-
butes to their therapeutic effects on negative and cognitive
symptoms.
4.2.3. Receptor polymorphisms
4.2.3.1. 5HT1A receptor. Multiple studies have investigated
an association between the T102C polymorphism of the 5HT1A
receptor and susceptibility for schizophrenia, with both primary
studies and meta-analyses producing mixed results [204–217].
An association of genotype distribution and allele frequency of
the 5-HTR1A C-1019G locus with schizophrenia has been
reported [218].
4.2.3.2. 5HT2A and 5HT2C receptors. Results from studies
investigating an association between 5HT2A receptor poly-
morphisms and response to antipsychotic treatment have been
variable and generally not significant. Some studies have
shown an association between the T102C polymorphism and
atypical antipsychotic response [219–221], while at least one
other has not [222]. The results of two studies have shown a
nonsignificant association between G-1438A polymorphism
variants and response to the atypical antipsychotics olanza-
pine or clozapine [223,224]. Studies investigating the
His452Tyr polymorphism have yielded mixed results, and in
those that found an association, it was not significant or not
replicated with the same significance in subsequent reports
[222,224–226].
985L.A. Catapano, H.K. Manji / Biochimica et Biophysica Acta 1768 (2007) 976–993Two 5HT2C polymorphisms have been shown to be asso-
ciated with response of schizophrenic patients to antipsychotic
treatment: the C-759T polymorphism in the promoter region
[227] and Cys23Ser [228].
4.3. G protein-coupled noradrenergic receptors and
schizophrenia
While a primary abnormality in the noradrenergic system has
not been demonstrated in schizophrenia, norepinephrine plays a
key role in regulating prefrontal cognitive function, which is
impaired in patients with this disorder. In addition, several
pharmacologic agents have effects on adrenergic receptors,
suggesting a potential, indirect role for this system in the
treatment of the disease.
4.3.1. Pharmacologic challenge studies
Recent studies have investigated the potential role of stress-
induced noradrenergic dysfunction of prefrontal cortical
function. The prefrontal cortex (PFC) allows us to appro-
priately guide our behaviors, thoughts, and emotions by using
representational knowledge [229]. Lesions of the prefrontal
cortex produce symptoms of impulsivity, distractibility, and
poor judgment; more extensive disruptions of prefrontal
cortical function may also contribute to thought disorder and
hallucinations—among the hallmarks of schizophrenia. It is
thus noteworthy that studies have shown that alpha1 adrenergic
antagonists (or agents affecting its signaling cascades, such as
protein kinase C) attenuate stress-induced PFC-mediated
cognitive deficits [229], and the alpha2-AR agonist clonidine
improves prefrontal cognitive functioning in patients with
schizophrenia [230]. Guanfacine, another alpha2A-AR agonist,
was demonstrated to be safe and efficacious in treating
cognitive impairment in schizophrenic patients when given as
an adjunctive treatment with risperidone in a placebo-
controlled, double-blind trial [231]. These findings raise the
possibility that some of the beneficial cognitive effects of
atypical antipsychotics like clozapine may be mediated by their
effects on alpha1 adrenergic receptors, and is worthy of further
study.
4.3.2. Effects of antipsychotic medications
Most atypical antipsychotics, as well as many typical anti-
psychotics including haloperidol, have high binding affinity for
alpha1-AR (reviewed in [140]), although the clinical signifi-
cance of this action is unclear. Some atypical antipsychotics,
including clozapine and risperidone, act as potent antagonists at
alpha2-ARs. It is hypothesized that this action contributes to
their antipsychotic effect by enhancing dopaminergic transmis-
sion in the frontal cortex relative to subcortical pathways via the
blockade of inhibitory alpha2-ARs on dopaminergic neuron
terminals [232,233].
4.3.3. Receptor polymorphisms
Clark and colleagues [234] identified two single nucleotide
polymorphisms (SNPs) in the promoter region of the alpha1A-
adrenergic receptor gene that are associated with schizophrenia.4.4. G protein-coupled cholinergic receptors and schizophrenia
4.4.1. Postmortem and pharmacologic studies
M1 receptor expression has been shown to be decreased in
the cortex of postmortem brains of schizophrenic patients
[235]. Muscarinic agonists are effective in animal models of
negative symptoms and cognitive dysfunction (reviewed in
[236,237]), and the atypical antipsychotics clozapine and
olanzapine act as partial agonists at cholinergic M1, M2 and
M4 receptors [140], although the clinical significance of these
actions is not known.
4.4.2. Receptor polymorphisms
Liao and colleagues [238] demonstrated an association
between the C267A polymorphism of the M1 cholinergic
receptor and performance of schizophrenic patients on the
Wisconsin Card Sorting Test, a measure of prefrontal cognitive
function. This polymorphism was not associated with suscept-
ibility to the disease or treatment response [238].
4.5. G protein-coupled glutamatergic receptors and
schizophrenia
There is now compelling evidence for the involvement of
the glutamatergic system in schizophrenia [239–241]. How-
ever, as is the case with mood disorders, the preponderance of
available data pertains to the role of ionotropic glutamatergic
receptors, and is not discussed here. The interested reader is
referred to several outstanding recent reviews on the topic
[239–241].
4.5.1. Pharmacologic studies
Growing interest in the glutamate system in schizophrenia
is based primarily on pharmacologic studies. Studies have
shown that Group I metabotropic glutamate receptor (mGluR1
and mGluR5) antagonists potentiate the schizophrenia-like
behavioral effects induced by phencyclidine (PCP) and
amphetamines (reviewed in [242]). Group I agonists inhibit
amphetamine-induced sensorimotor gating deficits [242] and
PCP-stimulated dopamine release in prefrontal cortex in rats
[243]. Group II receptor (mGluR2/3) agonists block PCP-
induced behavioral activation and working memory impair-
ment [244,245]. mGluR1 and mGluR5 knockout mice show
disruptions in sensorimotor gating, which is disrupted in
schizophrenia (reviewed in [242]).
4.5.2. Receptor polymorphisms
Several studies have examined the metabotropic glutamate
receptors for associations with schizophrenia. Fujii and
colleagues [246] found a single nuclear polymorphism (SNP)
in GRM3, the gene for mGluR3, to have a positive association
with schizophrenia. A second study failed to replicate these
results but identified another SNP in GRM3 associated with the
disease [247]. One study by Takaki and colleagues [248]
identified haplotypes of GRM8, the gene for mGluR8,
associated with schizophrenia, suggesting a susceptibility
locus in this gene.
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Major depression, bipolar disorder, and schizophrenia are
severe, chronic diseases that cause significant morbidity and
mortality, as well as extraordinary economic costs to patients,
their families, and society. Our limited but increasing
understanding of the etiology of these diseases comes from
the convergence of pharmacologic, postmortem, imaging and
genetic research. There is a clear need to elucidate the
molecular and cellular underpinnings of these disorders in
order to develop improved therapeutics. As we have reviewed
here, there is a considerable body of evidence both
conceptually and experimentally that supports abnormalities
in the regulation of GPCRs as integral to the underlying
neurobiology of schizophrenia and mood disorders. The
pathophysiology of these illnesses must account for profound
changes in cognition, mood, and motoric function, as well as
a constellation of neurovegetative features derived from
dysfunction in limbic-related regions, such as the hippocam-
pus, hypothalamus and brainstem. The highly integrated
monoamine and prominent neuropeptide pathways are known
to originate and project heavily within these regions of the
brain, and it is thus not surprising that abnormalities have
been noted in their function across clinical studies. In fact, the
contribution of these pathways to the pathophysiology of
these illnesses must be reasonably robust, given the variability
that might be expected in assessing such dynamic systems
under the constraints in experimental design imposed upon
such research. Through functional brain imaging studies,
circuits have been identified that mediate the behavioral,
cognitive, and somatic manifestations of schizophrenia and
mood disorders. Key areas of these circuits include the orbital
and medial prefrontal cortex, anterior cingulate, amygdala and
related limbic structures, medial thalamus, and related regions
of the basal ganglia. Imbalance within these circuits, rather
than an increase or decrease in any single neurotransmitter in
a given region of the circuit, seems to predispose to and
mediate the expression of the major psychiatric illnesses.
Treatments that more directly restore balance to these circuits
may prove more effective particularly in refractory cases.
It is also becoming increasingly clear that for many patients
with refractory illnesses, new drugs simply mimicking the
‘traditional’ drugs that directly or indirectly alter neurotrans-
mitter levels may be of limited benefit. This is clear because
such strategies implicitly assume that the target receptor(s) –
and downstream signal mediators – are functionally intact, and
that altered synaptic activity will thus be transduced to modify
the postsynaptic ‘throughput’ of the system. However, the
possible existence of abnormalities in GPCRs (and potentially
their signal transduction pathways) suggests that for patients
refractory to conventional medications, improved therapeutics
may only be obtained by the direct targeting of post-receptor
sites. Recent discoveries concerning a variety of mechanisms
involved in the formation and inactivation of second messen-
gers offer the promise for the development of novel pharma-
cological agents designed to target signal transduction pathways
(discussed in [249]).Although clearly more complex than the development of
receptor-specific drugs, it may be possible to design novel
agents to selectively affect second messenger systems, because
they are quite heterogeneous at the molecular and cellular level,
are linked to receptors in a variety of ways, and are expressed in
different stoichiometries in different cell types. Additionally,
since signal transduction pathways display certain unique
characteristics depending on their activity state, they offer
built-in targets for relative specificity of action, depending on
the ‘set-point’ of the substrate. These developments hold much
promise for the advancement of novel therapeutics for the long-
term treatment of these major psychiatric disorders. The
challenge for the next era in neuropsychopharmacology is to
transform the knowledge gained from advances in neurobiol-
ogy, cellular physiology and molecular pharmacology into
clinical use.
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